S-1: Odyssey Health Seeks $25M Capital Raise

Odyssey Health Incorporated filed an S-1 registration statement to allow Mast Hill Fund, L.P. to resell 20 million shares and potentially raise up to $25 million for general corporate purposes.

Summary

• Odyssey Health Inc. filed an S-1 registration statement for the resale of up to 20,000,000 shares of common stock by Mast Hill Fund, L.P.
• The company will not receive proceeds from Mast Hill Fund's resale of these shares.
• However, Odyssey Health may receive up to an additional $25,000,000 in gross proceeds from direct sales of its common stock to Mast Hill Fund over a 24-month period, contingent on the registration statement becoming effective.
• Proceeds received by the company are intended for general corporate purposes, capital expenditures, working capital, and general and administrative expenses, including potential officer and director compensation.
• As of August 4, 2025, there were 96,709,763 shares of common stock outstanding. Assuming the full issuance of the 20,000,000 shares, the total outstanding shares would be 116,709,763.
• The last reported sale price of the common stock on the OTCQB exchange (symbol ODYY) was $0.022 per share on August 1, 2025.
• The company is focused on developing and acquiring medical products and health-related technologies, specifically mentioning the CardioMap heart monitoring and screening device and the Save A Life choking rescue device.

Sentiment

Score: 3

Explanation: The filing indicates a critical need for capital, highlighted by the 'going concern' warning. While the potential $25M raise is positive for liquidity, the significant dilution, low stock price, and accrued executive compensation suggest underlying financial challenges and a high-risk investment profile. The company's development projects are promising but are still in early stages without clear market approval or revenue generation.

Positives

• Potential to raise up to $25,000,000 in gross proceeds from Mast Hill Fund over a 24-month period, providing necessary capital for operations.
• Management retains control over the timing and amount of future share sales to Mast Hill Fund.
• The Purchase Agreement can be terminated by the company at any time with one business day notice, without fee or penalty.
• The company has two development projects in 'life saving technologies': the CardioMap heart monitoring and screening device and the Save A Life choking rescue device.

Negatives

• The company will not receive any proceeds from the sale of the 20,000,000 shares by the selling stockholder, Mast Hill Fund.
• The auditor's report includes an explanatory paragraph regarding the company's ability to continue as a going concern, indicating significant financial uncertainty.
• The current market price of the common stock is very low at $0.022 per share as of August 1, 2025.
• Significant accrued salary and bonus for Joseph Michael Redmond ($1,330,308 as of July 31, 2025) and Christine M. Farrell ($476,925 as of July 31, 2025) which will be paid in cash or stock, potentially impacting cash flow or causing further dilution.

Risks

• The sale or issuance of common stock to Mast Hill Fund may cause substantial dilution to existing stockholders.
• The sale of shares by Mast Hill Fund, or the anticipation of such sales, could cause the stock price to fall.
• The company may require additional financing beyond the $25,000,000 from Mast Hill Fund to sustain operations, and future financing terms could adversely impact stockholders.
• There is no guarantee that an active trading market for the common stock will be sustained, which could impair investors' ability to sell shares and the company's ability to raise capital or acquire assets.
• Management has broad discretion over the use of proceeds from the Mast Hill Fund transaction, and the funds may not be invested successfully.
• The company does not anticipate paying dividends, meaning stockholders must rely solely on stock appreciation for returns, which is uncertain.
• The company may need to register additional shares beyond the 20,000,000 covered by this prospectus to receive the full $25,000,000 commitment, leading to further dilution.
• The Purchase Agreement prohibits the company from entering into certain 'Variable Rate Transactions,' which could limit future financing options.

Future Outlook

The company intends to acquire other technologies and assets, planning to become a trans-disciplinary product development company involved in the discovery, development, and commercialization of products and technologies across various medical markets. It aims to license, improve, and/or develop products and establish distribution channels, including direct marketing efforts and agreements with third-party distributors. The company also plans to engage third-party research and development firms and apply for trademarks and patents for proprietary products.

Management Comments

• Our corporate mission is to create or acquire distinct technologies and intellectual property with an emphasis on acquisition targets that will generate positive cash flow.
• Our business model is to develop or acquire unique medical related products, engage third parties to manufacture such products and then distribute the products through various distribution channels, including third parties.
• We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets.
• We intend to license, improve and/or develop our products and identify and select distribution channels.
• We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts.
• We will determine the most effective method of distribution for each unique product that we include in our portfolio.
• We intend to engage third party research and development firms who specialize in the creation of medical products to assist us in the development.
• We intend to apply for trademarks and patents as we develop proprietary products.

Industry Context

Odyssey Health operates within the medical products and health technology development sector, focusing on acquiring and developing technologies with identified advantages and substantial market opportunities. The company's strategy of developing or acquiring unique medical products and utilizing third-party manufacturing and distribution is common in the medical device industry, particularly for smaller companies seeking to minimize upfront capital expenditure. Its focus on 'life-saving technologies' like heart monitoring and choking rescue devices positions it in high-impact, potentially high-growth niches, though these also typically involve significant regulatory hurdles and R&D costs.

Comparison to Industry Standards

• The company's business model of developing or acquiring unique medical products and outsourcing manufacturing and distribution is a common strategy for smaller, development-stage medical device companies, similar to many biotech or med-tech startups that focus on R&D and intellectual property rather than large-scale manufacturing infrastructure.
• The reliance on a single institutional investor (Mast Hill Fund) for a significant capital raise, particularly through a fluctuating price mechanism, is typical for micro-cap or OTC-listed companies that may have limited access to traditional equity markets or larger institutional investors.
• The presence of a 'going concern' explanatory paragraph in the auditor's report is a significant red flag, indicating that the company's financial viability is in question, a common issue for early-stage or unprofitable companies in the R&D-heavy medical device sector. This contrasts sharply with established, cash-flow positive industry leaders like Medtronic or Johnson & Johnson, which have robust R&D budgets and diversified revenue streams.
• The low stock price of $0.022 per share places the company firmly in the penny stock category, which is associated with higher volatility and liquidity risks compared to larger, more established medical device companies traded on major exchanges.

Corporate Governance

Related Party Transactions

• Accrued salary and bonus for Joseph Michael Redmond ($1,330,308 as of July 31, 2025) and Christine M. Farrell ($476,925 as of July 31, 2025) which will be paid either in cash or stock at a future date.
• Issuance of stock options and restricted stock units to directors, officers, and employees in exchange for ongoing services.
• Promissory notes and amendments with directors and officers (e.g., December 21, 2021, amended multiple times).

Stakeholder Impact

• Shareholders: Significant potential for dilution due to the issuance of up to 20,000,000 shares to Mast Hill Fund and potentially more to reach the $25,000,000 commitment. The low stock price and 'going concern' warning indicate high risk to investment value.
• Employees/Management: Potential for continued employment and compensation, with accrued salaries and bonuses indicating deferred payments. The capital raise could secure their positions and future operations.
• Creditors: The capital raise could improve the company's ability to meet its financial obligations, potentially reducing credit risk.
• Customers/Suppliers: Continued operations and product development, supported by the capital raise, could ensure product availability and ongoing business relationships.

Next Steps

• The SEC must declare the S-1 registration statement effective before the company can commence sales to Mast Hill Fund.
• The company plans to direct Mast Hill Fund to purchase shares over a 24-month period after the registration statement becomes effective.
• The company intends to acquire other technologies and assets.
• The company plans to engage third-party research and development firms.
• The company intends to apply for trademarks and patents for proprietary products.
• The company plans to establish agreements with distributors and undertake direct marketing efforts.
• The company may need to register additional shares for resale to receive the full $25,000,000 commitment from Mast Hill Fund.

Key Dates

Recommendation

The S-1 filing reveals a company in a precarious financial position, evidenced by the auditor's 'going concern' warning. While the potential $25 million capital raise from Mast Hill Fund offers a lifeline, it comes with significant dilution risk to existing shareholders, especially given the current low stock price of $0.022. The company's reliance on this funding, coupled with substantial accrued executive compensation, suggests a strained balance sheet. The business model, while focused on promising medical technologies, is still in development, with no clear path to profitability or sustained positive cash flow. The high risk of further dilution, the 'going concern' issue, and the lack of a robust active trading market make this a highly speculative and unfavorable investment at this time. A seasoned investor would likely view this as a distressed asset with substantial downside risk.

Keywords

Odyssey Health, ODYY, S-1 Filing, SEC, Common Stock, Capital Raise, Dilution, Mast Hill Fund, Medical Devices, Health Technology, Going Concern, OTCQB, Public Offering, Registration Statement